Journal Home
Search for

Volume 104, Issue 4, Pages 534-541 (April 2010)


View previous. 8 of 19 View next.

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis

Brigitta U. MonzaCorresponding Author Informationemail address, Paul Sachsbc, Jeffrey McDonaldd, Bruce Crawforde, Michael C. Nivensf, Kay Tetzlafffg

Received 24 November 2008; accepted 31 October 2009. published online 17 November 2009.

Summary 

Background

To assess the responsiveness of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD and chronic bronchitis patients recovering from an acute exacerbation. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. The four domains (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels.

Methods

Outpatients were enrolled within 48h of symptom onset of their exacerbation. Treatment was initiated at the discretion of the investigator, and patients observed for 6 weeks. During study visits, 59 eligible patients completed the CASA-Q at enrolment, week 1, 2 and 6. Responsiveness was assessed by calculating standardized effect sizes.

Results

Of the 19 male and 40 female patients with a mean (standard deviation, SD) age of 61.1 (10.5) years, all were classified by their physician to have improved or recovered after six weeks. The mean (SD) CASA-Q sores for the cough symptom, cough impact, sputum symptom and sputum impact domains increased from 32.6 (21.0), 40.7 (22.4), 37.4 (20.1), 47.1 (24.2) at enrolment to 54.0 (19.8), 63.7 (21.3), 55.1 (19.0), 65.5 (20.5) at week 6, respectively. Standardized effect sizes for patients improved or recovered from their exacerbation at week 6 were above 1.0 for the cough domains and at least 0.77 for the sputum domains.

Conclusions

The CASA-Q was responsive to symptom changes in patients recovering from an exacerbation.

a Boehringer Ingelheim GmbH, Binger Strasse 173, D-55216 Ingelheim, Germany

b Stamford Hospital, Stamford, 190W. Broad Street, Stamford, CT 06902, United States

c Columbia University College of Physicians and Surgeons, NY, United States

d Mapi Values, 133 Portland Street, Boston, MA 02114, United States

e Mapi Values, Arco Tower 8F, 1-8-1 Shimomeguro, Meguro-ku, Tokyo 153 0064, Japan

f Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, United States

g Medical Clinic, Department of Sports Medicine, University of Tuebingen, Silcherstrasse 5, D-72076 Tuebingen, Germany

Corresponding Author InformationCorresponding author. Tel.: +49 6132 77 93362; fax: +49 6132 77 4233.

PII: S0954-6111(09)00361-8

doi:10.1016/j.rmed.2009.10.026


View previous. 8 of 19 View next.